Bio

Dr. Martin is an interventional radiologist with Stanford Health Care Interventional Radiology. She is also a clinical instructor in the Department of Radiology, Division of Nuclear Medicine and Molecular Imaging at Stanford University School of Medicine.

Dr. Martin specializes in interventional oncology (minimally invasive cancer treatments). She diagnoses and treats venous (vein) disease, including venous occlusion (when a vein becomes narrowed or blocked by nearby structures), deep vein thrombosis (DVT), and vascular malformations (abnormal development of blood vessels). She also focuses on the management of cirrhosis (severe scarring of the liver) and portal hypertension (elevated pressure in a large abdominal vein). Additionally, she treats women’s health issues, such as fallopian tube blockages and uterine fibroids.

Her research interests include treatments for portal vein thrombosis (clotting), liver cancer, and health care disparities. She has also studied intra-arterial corticosteroid treatment for inflammatory bowel disease. In addition, she has explored the use of bronchial artery embolization (blocking a blood vessel) for the treatment of hemoptysis (coughing up blood) in people with cystic fibrosis.

Dr. Martin twice received the Society of Interventional Oncology (SIO) Scholarship Award. She won first place in SIO’s Artificial Intelligence Hackathon. She has also twice received the Etta Kalin Moskowitz Fund Research Award.

Dr. Martin has published in peer-reviewed journals, including the Journal of Clinical Medicine, Neuropeptides, and Journal of Vascular and Interventional Radiology. She has delivered presentations at a number of professional society meetings, including the SIO, the Society of Interventional Radiology (SIR), and the Radiological Society of North America (RSNA).

Dr. Martin is a member of several professional groups, including SIO, SIR, and RSNA. She also serves on committees such as SIO’s Education Committee and Stanford’s Performance Improvement Committee.

Clinical Focus

  • Vascular and Interventional Radiology

Academic Appointments

  • Clinical Assistant Professor, Radiology

Professional Education

  • Board Certification: American Board of Radiology, Diagnostic Radiology (2024)
  • Residency: Stanford University Radiology Residency (2023) CA
  • Internship: Stanford University Dept of General Surgery (2018) CA
  • Medical Education: Boston University School of Medicine (2017) MA

Contact

  • Academic
    lbett@stanford.edu
    University - Academic staff Department: Rad/Interventional Radiology Position: Clinical Assistant Professor
  • Clinical (Primary)  Department of Radiology 300 Pasteur Dr MC 5105 Stanford, CA 94305 (650) 723-1909 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5105

Clinical Trials

  • Computational Drug Repurposing for All EBS Cases Recruiting

    The study will compare gene expression differences between blistered and non-blistered skin from individuals with all subtypes of EB, as well as normal skin from non-EB subjects. State of the art computational analysis will be performed to help identify new drugs that might help all EB wound healing and reduce pain. Researchers will focus on drugs that have already been approved for treatment of other dermatologic or non-dermatologic diseases, and therefore be repurposed for treatment of EB. Drug development is a very expensive process taking decades for execution. Drug repurposing on the other hand, significantly reduces the cost and shortens the amount of time that is needed to bring effective treatments to clinical use. To date, there is no specific treatment targeting the physiology and immunologic response in EB patients during wound healing. Market availability of repurposed medications will provide all EB patients rapid access to treatments, thus improving their quality of life.

    View full details

2024-25 Courses

All Publications

  • Endovascular Management of Non-Cirrhotic Acute Portomesenteric Venous Thrombosis. Journal of vascular and interventional radiology : JVIR Lorenz, J., Kwak, D. H., Martin, L., Kesselman, A., Hofmann, L. V., Yu, Q., Youssef, S., Ciolek, P., Ahmed, O. 2024

    Abstract

    Acute portomesenteric venous thrombosis (PVT) is a rare but potentially life-threatening condition in individuals without cirrhosis. Initial management typically involves anticoagulation therapy, but the optimal approach to interventional treatment remains a topic of ongoing research. This article explores both traditional and emerging endovascular techniques, providing an overview of the existing evidence supporting their use. Additionally, it delves into the significance of acute PVT in the context of contemporary pathologies, notably COVID-19 infection, vaccine-induced immune thrombotic thrombocytopenia, and liver transplantation.

    View details for DOI 10.1016/j.jvir.2024.09.023

    View details for PubMedID 39389231

  • What the Interventional Radiologist Needs to Know about the Genetics of Vascular Anomalies. Seminars in interventional radiology Josephs, S., Martin, L., Josephs, T., Hovsepian, D. 2024; 41 (4): 350-362

    Abstract

    The purpose of this article is to familiarize the reader with the basic genetics and vascular biology behind the array of vascular anomalies they may encounter in their practice. Individuals with vascular malformations are often referred to multidisciplinary clinics composed of diverse specialists all with the same goal: how to provide the best care possible. The team is typically composed of physicians, nurses, social workers, and technical staff from multiple specialties including diagnostic and interventional radiology, dermatology, hematology/oncology, otolaryngology, plastic surgery, and several additional subspecialties. Imaging plays a crucial role in diagnosis and treatment planning, but increasingly biopsies are needed for more accurate histopathological and genetic information to inform the plan of treatment, as well as for counseling patients and their families on the natural history, heritability, and long-term prognosis of the condition. Understanding the molecular mechanism that gives rise to vascular anomalies is crucial for arriving at the proper diagnosis and choosing among treatment options. As oncological medications are being increasingly repurposed to treat vascular malformations, it is vital for those caring for patients with vascular anomalies to understand how these anomalies develop, and which drug may be appropriate to repurpose for this benign disease.

    View details for DOI 10.1055/s-0044-1791204

    View details for PubMedID 39524236

    View details for PubMedCentralID PMC11543101

  • Volumetric Analysis: Effect on Diagnosis and Management of Indeterminate Solid Pulmonary Nodules in Routine Clinical Practice. Journal of computer assisted tomography Lim, R. S., Rosenberg, J., Willemink, M. J., Cheng, S. N., Guo, H. H., Hollett, P. D., Lin, M. C., Madani, M. H., Martin, L., Pogatchnik, B. P., Pohlen, M., Shen, J., Tsai, E. B., Berry, G. J., Scott, G., Leung, A. N. 2024

    Abstract

    To evaluate the effect of volumetric analysis on the diagnosis and management of indeterminate solid pulmonary nodules in routine clinical practice.This was a retrospective study with 107 computed tomography (CT) cases of solid pulmonary nodules (range, 6-15 mm), 57 pathology-proven malignancies (lung cancer, n = 34; metastasis, n = 23), and 50 benign nodules. Nodules were evaluated on a total of 309 CT scans (average number of CTs/nodule, 2.9 [range, 2-7]). CT scans were from multiple institutions with variable technique. Nine radiologists (attendings, n = 3; fellows, n = 3; residents, n = 3) were asked their level of suspicion for malignancy (low/moderate or high) and management recommendation (no follow-up, CT follow-up, or care escalation) for baseline and follow-up studies first without and then with volumetric analysis data. Effect of volumetry on diagnosis and management was assessed by generalized linear and logistic regression models.Volumetric analysis improved sensitivity (P = 0.009) and allowed earlier recognition (P < 0.05) of malignant nodules. Attending radiologists showed higher sensitivity in recognition of malignant nodules (P = 0.03) and recommendation of care escalation (P < 0.001) compared with trainees. Volumetric analysis altered management of high suspicion nodules only in the fellow group (P = 0.008). κ Statistics for suspicion for malignancy and recommended management were fair to substantial (0.38-0.66) and fair to moderate (0.33-0.50). Volumetric analysis improved interobserver variability for identification of nodule malignancy from 0.52 to 0.66 (P = 0.004) only on the second follow-up study.Volumetric analysis of indeterminate solid pulmonary nodules in routine clinical practice can result in improved sensitivity and earlier identification of malignant nodules. The effect of volumetric analysis on management recommendations is variable and influenced by reader experience.

    View details for DOI 10.1097/RCT.0000000000001630

    View details for PubMedID 38968327

  • Case Series of Precision Delivery of Methylprednisolone in Pediatric Inflammatory Bowel Disease: Feasibility, Clinical Outcomes, and Identification of a Vasculitic Transcriptional Program. Journal of clinical medicine Levitte, S., Yarani, R., Ganguly, A., Martin, L., Gubatan, J., Nadel, H. R., Franc, B., Gugig, R., Syed, A., Goyal, A., Park, K. T., Thakor, A. S. 2023; 12 (6)

    Abstract

    Systemic steroid exposure, while useful for the treatment of acute flares in inflammatory bowel disease (IBD), is associated with an array of side effects that are particularly significant in children. Technical advancements have enabled locoregional intraarterial steroid delivery directly into specific segments of the gastrointestinal tract, thereby maximizing tissue concentration while limiting systemic exposure. We investigated the feasibility of intraarterial steroid administration into the bowel in a cohort of nine pediatric patients who had IBD. This treatment approach provided symptom relief in all patients, with sustained relief (>2 weeks) in seven out of nine; no serious adverse effects occurred in any patient. In addition, we identified patterns of vascular morphologic changes indicative of a vasculopathy within the mesenteric circulation of inflamed segments of the bowel in pediatric patients with Crohn's disease, which correlated with disease activity. An analysis of publicly available transcriptomic studies identified vasculitis-associated molecular pathways activated in the endothelial cells of patients with active Crohn's disease, suggesting a possible shared transcriptional program between vasculitis and IBD. Intraarterial corticosteroid treatment is safe and has the potential to be widely accepted as a locoregional approach for therapy delivery directly into the bowel; however, this approach still warrants further consideration as a short-term "bridge" between therapy transitions for symptomatic IBD patients with refractory disease, as part of a broader steroid-minimizing treatment strategy.

    View details for DOI 10.3390/jcm12062386

    View details for PubMedID 36983386

  • Bronchial Artery Embolization for Hemoptysis in Cystic Fibrosis Patients: A 17-Year Review. Journal of vascular and interventional radiology : JVIR Martin, L. N., Higgins, L., Mohabir, P., Sze, D. Y., Hofmann, L. V. 2019

    Abstract

    PURPOSE: To review safety and efficacy of bronchial artery embolization (BAE) for treatment of hemoptysis in adult patients with cystic fibrosis (CF) and to report 30-day, 1-year, and 3-year outcomes.MATERIALS AND METHODS: Between January 2001 and April 2018, 242 patients with CF were evaluated for hemoptysis. Thirty-eight BAEs were performed in 28 patients with hemoptysis. Technical success was defined as freedom from repeat embolization and hemoptysis-related mortality. Clinical success was defined as freedom from repeat embolization and mortality from any cause. Technical and clinical success were examined at 30 days, 1 year, and 3 years after initial BAE. Mean patient age was 32 years, and median follow-up was 4.8 years (range, 10 mo to 16.7 y).RESULTS: Technical and clinical success rates at 30 days were 89% (25/28) and 82% (23/28), respectively. Success rates at 1 year were 86% (24/28) and 79% (22/28), respectively, and at 3 years were 82% (23/28) and 75% (21/28), respectively. The 30-day overall complication rate was 7.9% (3/38) with 2.6% (1/38) major complication rate and 5.2% (2/38) minor complication rate. Overall 3-year mortality rate was 25% (7/28).CONCLUSIONS: BAE is safe and effective in patients with CF presenting with life-threatening hemoptysis. BAE results in high rates of long-term technical and clinical success in this patient population despite progressive chronic disease. Repeat embolization is necessary only in a minority of patients.

    View details for DOI 10.1016/j.jvir.2019.08.028

    View details for PubMedID 31899109